Two late-breaking clinical trials on trans catheter valves to treat congenital heart disease were presented at the 2020 Society for Cardiovascular Angiography and Interventions (SCAI) virtual Scientific Sessions. These included the 10-year outcomes from the Melody Transcatheter Pulmonary Valve (TPV) demonstrating strong long-term hemodynamic and safety outcomes. The other was the first results from the investigational Harmony TPV pivotal trial met safety and efficacy endpoints for hemodynamic function at six months.
|